扭转平衡:以理性联合治疗克服套细胞淋巴瘤中的维奈克拉耐药
套细胞淋巴瘤(MCL)以t(11;14)易位和Cyclin D1过表达为遗传学特征,BCL-2家族蛋白BCL-2、BCL-XL与MCL-1的失调在此病中十分常见。BCL-2抑制剂维奈克拉(ABT-199)已在MCL早期临床试验中显示良好结果,但相当一部分患者存在原发耐药或长期治疗后出现耐药。本文综述维奈克拉耐药机制(如BCL-XL或MCL-1上调)及BCL-2家族抑制剂研发进展,并讨论理性联合治疗策略。
要点
- MCL中BCL-2、BCL-XL与MCL-1失调常见,使BCL-2家族成为有吸引力的治疗靶点。
- 维奈克拉在MCL早期临床试验中显示良好结果,但部分患者原发耐药或长期治疗后耐药。
- BCL-XL或MCL-1上调是维奈克拉耐药的机制之一,联合治疗有望克服耐药。
核心结论
- MCL中维奈克拉耐药可由BCL-XL或MCL-1上调等机制介导,基于这些机制的理性联合治疗有望预防或克服耐药并改善患者结局。
研究设计与样本
- 综述,围绕MCL中维奈克拉耐药机制、BCL-2家族抑制剂研发进展及转录与(后)翻译调控和淋巴器官微环境作用进行汇总与讨论。
主要发现
- MCL为侵袭性但不可治愈的B细胞淋巴瘤,遗传学特征为t(11;14)易位导致Cyclin D1过表达。
- BCL-2家族蛋白BCL-2、BCL-XL和MCL-1的失调在MCL中高度常见。
- 维奈克拉(ABT-199)已获FDA批准用于慢性淋巴细胞白血病(CLL)和急性髓系白血病(AML),在MCL早期临床试验中显示良好结果。
- 相当一部分MCL患者对维奈克拉原发耐药,或长期治疗后发生耐药,机制包括BCL-XL或MCL-1上调。
临床怎么用
- 作者认为,基于耐药机制的维奈克拉与其他治疗的理性联合可望用于预防或克服维奈克拉耐药并改善MCL患者结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL), an aggressive, but incurable B-cell lymphoma, is genetically characterized by the t(11;14) translocation, resulting in the overexpression of Cyclin D1. In addition, deregulation of the B-cell lymphoma-2 (BCL-2) family proteins BCL-2, B-cell lymphoma-extra large (BCL-XL), and myeloid cell leukemia-1 (MCL-1) is highly common in MCL. This renders these BCL-2 family members attractive targets for therapy; indeed, the BCL-2 inhibitor venetoclax (ABT-199), which already received FDA approval for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), shows promising results in early clinical trials for MCL. However, a significant subset of patients show primary resistance or will develop resistance upon prolonged treatment. Here, we describe the underlying mechanisms of venetoclax resistance in MCL, such as upregulation of BCL-XL or MCL-1, and the recent (clinical) progress in the development of inhibitors for these BCL-2 family members, followed by the transcriptional and (post-)translational (dys)regulation of the BCL-2 family proteins, including the role of the lymphoid organ microenvironment. Based upon these insights, we discuss how rational combinations of venetoclax with other therapies can be exploited to prevent or overcome venetoclax resistance and improve MCL patient outcome.
引用
- Thus YJ, Eldering E, Kater AP, et al. Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma. Leukemia. 2022. PMID: 35725771. doi:10.1038/s41375-022-01627-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。